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Interleukin-17A (IL-17A) is a pro-inflammatory cyto-
kine linked to rapid malignant progression of colo-
rectal cancer (CRC) and therapy resistance. IL-17A
exerts its pro-tumorigenic activity through its type
A receptor (IL-17RA). However, IL-17RA is expressed
in many cell types, including hematopoietic, fibro-
blastoid, and epithelial cells, in the tumor microenvi-
ronment, and how IL-17RA engagement promotes
colonic tumorigenesis is unknown. Here we show
that IL-17RA signals directly within transformed
colonic epithelial cells (enterocytes) to promote early
tumor development. IL-17RA engagement activates
ERK, p38 MAPK, and NF-kB signaling and promotes
the proliferation of tumorigenic enterocytes that just
lost expression of the APC tumor suppressor.
Although IL-17RA signaling also controls the pro-
duction of IL-6, this mechanism makes only a par-
tial contribution to colonic tumorigenesis. Combined
treatment with chemotherapy, which induces IL-17A
expression, and an IL-17A neutralizing antibody
enhanced the therapeutic responsiveness of estab-
lished colon tumors. These findings establish IL-
17A and IL-17RA as therapeutic targets in colorectal
cancer.
INTRODUCTION
A link between inflammation and cancer has long been sus-
pected, but direct experimental evidence linking the two patho-
logical processes has only become available in recent decades.1052 Immunity 41, 1052–1063, December 18, 2014 ª2014 Elsevier InChronic inflammation associated with infection and autoimmune
disease increases cancer risk and accelerates progression of
many malignancies, including stomach, liver, and colon cancers
(Balkwill and Mantovani, 2001; Grivennikov et al., 2010). Pro-in-
flammatory cytokines and tumor-infiltratingmyeloid and immune
cells play critical roles in almost every stage of tumorigenesis,
from initiation and tumor promotion to malignant progression
and metastatic spread. Even in cancers that do not arise in the
context of underlying inflammation, a tumor-evoked inflamma-
tory response plays an important promoting role in malignant
progression (Grivennikov et al., 2012).
Among inflammatory cytokines that promote tumor develop-
ment, the interleukin-17 (IL-17) family, which includes IL-17A,
B, C, D, E, and F (Dungan andMills, 2011), occupies an important
position in both mouse models and human cancer. IL-17A and F
are the closest members of this family, and both bind to IL-17
receptors A (IL-17RA) and C (IL-17RC), whose engagement
activates mitogen-activated protein kinases (MAPKs), nuclear
factor-kappa B (NF-kB), and CCAAT-enhancer-binding protein
(C/EBP) signaling pathways through the adaptor proteins Act1
and TRAF6 (Iwakura et al., 2011; Reynolds et al., 2010). IL-17A
and F are produced by Th17 cells, gdT cells, natural killer T
(NKT) cells, and subsets of innate lymphoid cells (ILCs) (Rey-
nolds et al., 2010; Sutton et al., 2012; Zou and Restifo, 2010).
Initial evidence for the involvement of IL-17 cytokines in cancer
development came from studies of mouse colonic tumorigen-
esis. With the ApcMin model, it was shown that infection of
mice with the human enterotoxigenic Bacteroides fragilis
(ETBF) bacteria triggers colitis and accelerates IL-17A-depen-
dent tumor development (Wu et al., 2009). Neutralization of
IL-17A with a specific antibody prevented ETBF-induced accel-
eration of colonic tumorigenesis (Wu et al., 2009). Retrospective
clinical studies revealed that high IL-17A expression in stage I or
II human colorectal tumors is associated with rapid progression
to lethal metastatic disease and thus serves as a strong indicatorc.
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studies demonstrated that IL-17A also enhances development
of colitis-associated cancer (CAC) induced by the pro-carcin-
ogen azoxymethane (AOM) and the irritant dextran sulfate so-
dium (DSS) (Hyun et al., 2012; Tanaka et al., 2003; Tong et al.,
2012). Although IL-17A and IL-17F are related and signal through
the same receptors and effector mechanisms, IL-17F was re-
ported to attenuate CAC development (Tong et al., 2012). The
divergent roles of IL-17A and IL-17F in CAC can be explained
by their distinct functions in autoimmune- and chemically-
induced inflammation, which is a critical step in CAC induction
(Yang et al., 2008). Other studies, however, have shown that
genetic ablation of either IL-17A or IL-17F attenuates tumor
development in ApcMin mice, although the effect of IL-17A is
much more pronounced (Chae and Bothwell, 2011; Chae et al.,
2010).
A useful mouse model of colorectal tumorigenesis is provided
by the so-called CPC-APCmouse, in which one allele of the Apc
tumor suppressor gene is deleted in the colon and in which
subsequent Apc loss-of-heterozygocity (LOH) results in devel-
opment of large colonic adenomas that progress to invasive
carcinomas (Hinoi et al., 2007). Using this model, we found
that early colonic adenomas exhibit substantial upregulation of
IL-23 expression by tumor-associated myeloid cells (TAMs) as
a result of the loss of both protective mucin expression and tight
junctions between intestinal epithelial cells (IECs), which result in
invasion of the barrierless adenomas by components of the mi-
crobiome (Grivennikov et al., 2012). A similar process can occur
in human colonic adenomas, which also exhibit loss of mucins
and junctional adhesion molecules. IL-23 induces tumoral
expression of IL-17A, and ablation of IL-17RA inhibited colon
tumor development and progression in CPC-APC mice. These
results established the pro-tumorigenic function of a cytokine
cascade in which IL-23 produced by TAM controls IL-17A pro-
duction by Th17 and other lymphoid cells within the tumormicro-
environment and in which IL-17A stimulates tumor development
through IL-17RA (Grivennikov et al., 2012). More recently, it was
shown that IL-17C also stimulates tumor development in ApcMin
mice (Song et al., 2014), presumably through IL-17RA as well.
However, the mechanism by which IL-17RA engagement pro-
motes CRC development is not clear, and the cell type in which
it acts has not been identified. Whereas IL-23 receptor is
expressed on hematopoietic cell types and not on adenoma
epithelial cells (Grivennikov et al., 2012), many cell types,
including epithelial cells, hematopoietic cells, and fibroblasts,
express IL-17RA in the tumor microenvironment (Iwakura et al.,
2011; Reynolds et al., 2010).
Here we show that IL-17RA mainly signals within transformed
IECs to promote their growth and survival. IL-17RA signaling was
required for outgrowth of aberrant crypt foci (ACF) into colonic
tumors during the early phase of CRC development. Immune
neutralization of IL-17A could inhibit tumor progression and
sensitize established tumors to chemotherapy.
RESULTS
IL-17RA Signals in Transformed Epithelial Cells
IL-17 cytokines promote tumor development in mouse models
of colitis-associated or sporadic colorectal cancer by binding toImmIL-17RA (Chae and Bothwell, 2011; Chae et al., 2010; Grivenni-
kov et al., 2012; Hyun et al., 2012; Song et al., 2014; Tanaka
et al., 2003; Tong et al., 2012; Wu et al., 2009). However, it
is not known whether IL-17RA engagement exerts its pro-
tumorigenic effect directly within epithelial cells or whether,
akin to IL-23R (Grivennikov et al., 2012), it acts by controlling
production of other pro-tumorigenic cytokines by myeloid cells
or cancer-associated fibroblasts (CAFs), which also express IL-
17RA (Iwakura et al., 2011; Korn et al., 2009). To understand
how IL-17RA promotes colorectal tumorigenesis, we employed
the CPC-APC model (Hinoi et al., 2007) as previously described
(Grivennikov et al., 2012). An absence of IL-17RA in all cells of
CPC-APC mice resulted in a marked reduction in tumor cell
proliferation and increased apoptosis (Figures 1A and 1B).
Loss of IL-17RA also resulted in reduced IL-6 expression and
consequently decreased signal transducer and activator of
transcription (STAT3) activation in adenoma epithelial cells (Fig-
ures 1A–1C and Figure S1 in the Supplemental Information
available online), whereas stimulation of CAFs isolated from
CPC-APC tumors with recombinant IL-17A resulted in IL-6
mRNA induction (Figure 1D). Activation of Akt and, to a lesser
extent, ERK signaling in tumors was also reduced after
IL-17RA ablation (Figure 1E). Expression of other inflammatory
cytokines, including IL-21 and TNF, in tumors was elevated
upon loss of IL-17RA, although expression of the anti-inflam-
matory and anti-tumorigenic cytokines IL-10 and transforming
growth factor-b1 (TGFb1) (Becker et al., 2004; Mumm et al.,
2011) was also elevated (Figure S1). The expression of
IL-17C, and the IL-17-related chemokines CXCL1 and
CXCL2, was significantly elevated in tumors compared to
normal colon tissue and was reduced in Il17ra-null mice (Fig-
ure S1). IL-17A, IL-17F, and IL-11 were barely affected by
Il17ra ablation (Figure S1). The amounts of IL-17RC and
IL-17RE mRNAs, which interact with IL-17RA to mediate IL-
17A, C, and F signaling, were upregulated in Il17ra-ablated
tumors, possibly as a result of compensation (Figure S1).
The expression of several cytotoxic-response markers was
elevated in the absence of IL-17RA (Figure S2A). Loss of
IL-17RA resulted in decreased infiltration of myeloid cells
into tumors but had no observable impact on angiogenesis,
the formation of lymphatic vessels, or recruitment of CAFs
(Figures S2B and S2C). The mRNAs for Lgr5, Sox9, and
Msi1, markers of intestinal stem cells and targets of Wnt
signaling, were upregulated in colonic tumors but were not
affected by the absence of IL-17RA, although tumoral expres-
sion of Bmi1 mRNA was slightly elevated after IL-17RA ablation
(Figure S2D).
To test the role of IL-17RA signaling in hematopoietic cells dur-
ing CRC development, we adoptively transferred heterozygous
or Il17ra/ bone marrow into irradiated CPC-APC mice. An
absence of IL-17RA in hematopoietic cells had no effect on
colonic tumor development (Figure S3A). In contrast, reciprocal
bone marrow transfer into Il17ra/ CPC-APC mice showed that
Il17ra ablation in radio-resistant cells significantly decreased tu-
mor development (Figure 1F). After adoptive bonemarrow trans-
fer, at least 90% of the CD45+ cells were donor derived, ruling
out the possibility that residual recipient cells were masking
the effect of the IL-17RA deficiency within donor hematopoietic
cells (Figure S3B). Consistent with whole-body Il17ra ablation,unity 41, 1052–1063, December 18, 2014 ª2014 Elsevier Inc. 1053
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Figure 1. IL-17RA Exerts Its Pro-tumorigenic Activity within Radio-Resistant Cells
(A–E) Five-month-old CPC-APC mice heterozygous (+/) or null (/) for Il17ra were sacrificed for cryosectioning and immunostaining (A, B), ELISA (C), or
immunoblot analysis (E) of colonic tumors. Data in (B) were determined from a count of tumor epithelial cells positive for the indicated markers in five high-
magnification fields (HMFs). AU: artificial unit. (D) CAFs isolated from colonic tumors were stimulated with 50 ng/ml recombinant IL-17A for 4 hr and analyzed by
qRT-PCR analysis for IL-6 mRNA expression (n = 5).
(F) CPC-APC mice heterozygous (HE) or null (KO) for Il17ra were lethally irradiated at 6 weeks of age and transplanted with bone marrow of the indicated Il17ra
genotypes. At 5 months of age the mice were sacrificed, and tumor number and size (diameter) were measured. Tumor load is the sum of all tumor diameters. n =
4. Data represent averages ± SEM. *p < 0.05. The scale bar represents 100 mm. See also Figures S1–S3.
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Figure 2. IL-17RA Signals within APC-Deficient Enterocytes to Promote Tumor Development and Activate ERK, p38 MAPK, and NF-kB
Signaling
(A) Agarose gel image of PCR-mediated genotyping of the floxed and wild-type (WT) Il17ra alleles (upper panel) and the Cre-mediated deletion product (KO, lower
panel). The Il17raF allele came from the newly generated Il17raF/+ strain, whereas the null allele (-) was from a whole-body Il17ra ablation (Ye et al., 2001).
(B and C) Colonic IECs isolated by EpCAM-biotin staining and magnetic-bead enrichment were stimulated with 50 ng/ml IL-17A for the indicated periods before
immunoblot (B) and qRT-PCR analysis (C); n = 4.
(D) Tumor number, size, and load in CPC-APC mice (Cdx2Cre ApcF/+) harboring a specific deletion of IL-17RA in APC-deleted cells (F/-). Il17raF/+ CPC-APC mice
were used as controls. n = 6.
(E) Representative images of CPC-APC tumor-bearing colons that either express (F/+) or do not express (F/-) IL-17RA in APC-deleted enterocytes.
(F and G) APC-deleted intestinal organoids were stimulated with 50 ng/ml IL-17A for the indicated times. Whole-cell lysates (F), cytosol, and nuclear extract (G)
were collected, gel separated, and immunoblotted for the indicated proteins. Data are averages ± SEM. *p < 0.05. See also Figure S4.
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also showed increased expression of interferon-g (IFNg), per-
forin, granzyme B, and IL-10 (Figure S3C). The amounts of IL-
21 and IL-22 mRNAs were also higher in tumors of mice lacking
IL-17RA in hematopoietic cells (Figure S3C).
IL-17RA is expressed in colonic epithelial cells, CAFs, and
different subsets of immune and myeloid cells (Figure S4A). To
test whether IL-17RA signals directly within colonic epithelial
cells to promote CRC development, we generated a conditional
Il17ra knockout mouse (Figure S4B). Insertion of a LacZ cassetteImmallowed expression of b-galactosidase under control of the
Il17ra promoter. FLP-mediated deletion of the LacZ cassette
generated an Il17raF allele with two Loxp sites flanking exons
3 and 4. Cre-mediated deletion generated a frame shift in
exon 5, resulting in expression of a non-functional, truncated
N-terminal IL-17RA fragment (Figure 2A and Figure S4B).
Cdx2Cre-mediated ablation of the Il17raF allele in mice containing
one Il17ra-null allele resulted in nearly complete depletion of IL-
17RA mRNA in isolated IECs, which showed a marked decrease
in IL-17A-induced ERK phosphorylation (Figures 2B and 2C andunity 41, 1052–1063, December 18, 2014 ª2014 Elsevier Inc. 1055
A B Figure 3. IL-6 Contributes to the Develop-ment of Colonic Tumors but Not to IL-17A
Expression
CPC-APCmice heterozygous (+/) or null (/) for
Il6were sacrificed at 5months of age and analyzed
for tumor parameters (A) (n = 5) or IL-17AmRNA by
qRT-PCR ofmesenteric lymph node (MLN), normal
colon (N), and tumor (T) tissues (B) (n = 9). Data
represent averages ± SEM. See also Figure S5.
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IL-17A was probably due to their contamination with other cell
types that retain IL-17RA expression. Consistent with the results
of the reciprocal bone marrow transfer described above, dele-
tion of the Il17ra in intestinal epithelial and tumor cells resulted
in a marked decrease in the number, size, and load of colon
tumors (Figures 2D and 2E). The strong effect on tumor multi-
plicity suggested that IL-17A acts early in the tumorigenic
process.
To better examine the downstream signals that might mediate
IL-17RA effects on the survival and proliferation of cancer cells,
we stimulated Apc-deleted organoids derived from cultured
intestinal crypts (Sato et al., 2009) of VillinCre-ERT2 ApcF/F mice
(el Marjou et al., 2004) with recombinant IL-17A. 4-OH-tamox-
ifen-induced deletion of Apc, via Cre-ERT2-mediated recombi-
nation, resulted in a change in organoid morphology to a perfect
spherical structure in 3D culture (Figure S4D). Apc-deleted orga-
noids grew faster than wild-type (WT) organoids and were resis-
tant to withdrawal of growth factors from the culture medium
(Figure S4D). Stimulation of the transformed organoids with IL-
17A strongly and rapidly activated ERK, p38 MAPK, and NF-
kB signaling but had only a modest and delayed effect on
STAT3 and JNK (Figures 2F and 2G). IL-17A did not affect nu-
clear b-catenin in transformed organoids (Figure 2G). In sum-
mary, IL-17RA signaling seems to mainly affect the ERK, p38,
and NF-kB pathways.
IL-17RA Controls IL-6, but IL-6 Does Not Control
Tumoral IL-17A Expression
As described above, IL-17RA ablation decreases expression of
IL-6, a cytokine that contributes to the development of CAC
(Bollrath et al., 2009; Greten et al., 2004; Grivennikov and Karin,
2008). We therefore investigated the contribution of IL-6 to
colonic tumorigenesis in CPC-APC mice. Il6 gene ablation in
CPC-APCmice also resulted in reduced colonic tumor load (Fig-
ure 3A), but its effect was milder than the effect of the IL-17RA
deficiency. Furthermore, expression of IL-17A and RORgt, the
transcription factor required for IL-17A production, was barely
affected by the loss of IL-6 in the tumors, suggesting that IL-6
acts downstream of IL-17 during colonic tumor development
(Figure 3B and Figure S5). Deletion of IL-6, however, resulted
in increased expression of IL-1a, IL-1b, TNF, and IFNg mRNAs
in tumors (Figure S5). Notably, IL-1b and IL-21 are also known
to promote IL-17A production in both Th17 cells and gdT cells
(Cua and Tato, 2010), suggesting that in the absence of IL-6
theymight induce expression of IL-17A in tumor-associated lym-
phocytes. Consistent with the notion that IL-6 inhibits the devel-
opment of regulatory T (Treg) cells, the Treg marker Foxp3 was1056 Immunity 41, 1052–1063, December 18, 2014 ª2014 Elsevier Inelevated in colonic tumors of IL-6-deficient mice (Figure S5).
Thus, IL-17RA signaling modulates the expression of several cy-
tokines, including IL-6, whose pro-tumorigenic activity is less
potent than that of IL-17A.
IL-17RA Signaling Is Required for Growth of Aberrant
Crypt Foci
Disruption of the intestinal epithelial barrier during early tumori-
genic progression due to loss of mucins and junctional adhesion
proteins is followed by localized ‘‘tumor-elicited inflammation’’
that promotes colonic adenoma growth (Grivennikov et al.,
2012). To test whether IL-17RA signaling is required for early
tumor development, we employed a model of synchronized
intestinal tumorigenesis based on tamoxifen treatment of
Cdx2Cre-ERT2 ApcF/F mice (Feng et al., 2011; Feng et al., 2013).
One week after tamoxifen-induced biallelic Apc deletion, the re-
sulting ACF lesions showed increased b-catenin expression and
cell proliferation and lost expression of MUC2, and colon tissues
showed upregulation of IL-17A (Figures 4A and 4B and Fig-
ure S6A). Starting at twoweeks after tumor induction, expression
of IL-17C and F mRNAs was also increased (Figure S6B). Abla-
tion of Il17ra in this model led to a significant reduction in the
number of visible tumors detected 4weeks after tamoxifen injec-
tion (Figure 4C). To confirm a role for IL-17A signaling in early
tumor development, we injected Cdx2Cre-ERT2 ApcF/F mice with
an IL-17A-neutralizing antibody after the last round of tamoxifen
administration and still observed significantly reduced numbers
of colonic tumors (Figure 4D). Consistent with the notion that
IL-17RA mainly signals in transformed colonic epithelial cells to
promote CRC development, ablation of IL-17RA in hematopoiet-
ic cells by adoptive bone marrow transfer 3.5 months prior to
tamoxifen-induced tumorigenesis resulted in no significant
change in tumor multiplicity in this model (Figure S6C). Ablation
of IL-17RA signaling in Apc-deleted mice had no significant ef-
fect on apoptosis (caspase 3 cleavage), but it significantly
reduced cell proliferation within ACF lesions defined by regions
with upregulation of b-catenin and loss of goblet cells (Figures
4E and 4F). The change in cell proliferation was restricted to
transformed cells, as indicated by the fact that Cdx2Cre-ERT2-
negativemice showed no signs of reduced normal crypt cell pro-
liferation upon IL-17RA ablation (Figure S6D). Consistent with
the ability of IL-17RA to activate NF-kB, ACF in Il17ra/
Cdx2Cre-ERT2 ApcF/F mice showed reduced nuclear (activated)
NF-kB p65 staining in transformed cells identified by upregula-
tion of b-catenin and loss of mucin production in ACF lesions
(Figures 4E and 4F). These data suggest that IL-17RA signaling
stimulates the progression of early ACF lesions to adenomas
by promoting the proliferation of transformed cells.c.
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Figure 4. IL-17RA Signaling Is Required for the Growth of Aberrant Crypt Foci
Cdx2Cre-ERT2ApcF/F mice were injected with tamoxifen for intestinal tumor induction. (A) qRT-PCR analysis of IL-17A mRNA in colon tissues following tamoxifen
injection. n = 8.
(B) Immunostaining of MUC2 in colon cryosections 1 week after tamoxifen injection. Tamoxifen-injected Cdx2Cre-ERT2-negative mice were used as controls.
Arrows indicate areas of MUC2 loss. Representative images of three slides of each specimen are shown.
(C) Cdx2Cre-ERT2 ApcF/F mice heterozygous (+/) or null (/) for Il17ra were sacrificed for colon tumor count 4 weeks after tamoxifen injection. n = 5.
(D) Cdx2Cre-ERT2 ApcF/F mice were given tamoxifen via intraperitoneal injection. Starting one day after the last tamoxifen dose, mice received intraperitoneal
injections of 500 mg of isotype control or anti-IL-17A antibody on a weekly basis. Colon tumors were counted 4 weeks after last tamoxifen injection. n = 7.
(E and F) Immunostaining of colon cryosections from Cdx2Cre-ERT2 ApcF/F mice heterozygous (+/) or null (/) for Il17ra 2 weeks after tamoxifen injection. (F)
Quantification of Ki-67 (n = 4) and phospho-NF-kB p65 (P-p65; n = 7)-positive transformed cells in HMFs of tamoxifen-induced ACF lesions. Data shown in
arbitrary units (AU) represent averages ± SEM. *p < 0.05. The scale bar represents 100 mm. See also Figure S6.
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Chemotherapy
We investigated whether IL-17A neutralization can be used to
block the growth of colonic tumors. Intraperitoneal injection of
IL-17A-neutralizing antibody into CPC-APC mice with estab-
lished colonic tumors resulted in reduced NF-kB activation andImmcancer cell proliferation (Figures 5A and 5B). Long-term antibody
treatment starting at 2 months of age reduced tumor load in
these mice compared to CPC-APC mice receiving isotype con-
trol (Figures 5C and 5D). These data suggest that IL-17A neutral-
ization can inhibit the development, progression, and survival of
colonic tumors.unity 41, 1052–1063, December 18, 2014 ª2014 Elsevier Inc. 1057
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Figure 5. IL-17A-Neutralizing Antibody Reduces Colonic Tumor Load
(A and B) Five-month-old CPC-APCmice were injected with isotype control or anti-IL-17A antibodies for 2 weeks at 500 mg/injection/week. (A) Immunostaining of
cryosections of colonic tumors. (B) Quantitation of P-p65- (n = 10) and Ki-67 (n = 6)-positive cells in HMFs from (A).
(C and D) 2-month-old CPC-APC mice were injected weekly with isotype control or anti-IL-17A antibodies and sacrificed at 5 months of age for bright-field
imaging (C) and analysis of tumor parameters (D) (n = 6). Data are averages ± SEM. *p < 0.05. The scale bar represents 100 mm.
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sected or in combination with surgical removal of primary tumors
(Andre´ et al., 2004). However, chemotherapy also causes muco-
sitis and induces inflammation that curtails its anti-tumor effect
by upregulating cytokines that promote tumor growth and sur-
vival (Bruchard et al., 2013). In our model of sporadic colonic
tumorigenesis, treatment of CPC-APC mice with 5-FU, a
commonly used chemotherapeutic agent in CRC, resulted in
increased expression of IL-17A and F mRNAs in tumors (Fig-
ure 6A). By itself, this treatment regimen did not result in statisti-
cally significant tumor shrinkage (Figure 6B). To test whether IL-
17A neutralization during chemotherapy can potentiate the
response to 5-FU, we treated CPC-APC mice that had estab-
lished colonic tumors with anti-IL-17A and 5-FU for 6 weeks
starting at 3.5 months of age. This combination resulted in a
reduction in tumor size and load compared to those in mice
treated with either agent alone (Figure 6B). Neutralization of IL-
17A in 5-FU-treated mice also decreased expression of IL-61058 Immunity 41, 1052–1063, December 18, 2014 ª2014 Elsevier InmRNA in tumors (Figure 6C). The combined treatment with
IL-17A antibody and 5-FU led to a small decrease in cell prolifer-
ation and enhanced apoptosis in established colonic tumors
(Figures 6D and 6E). These results suggest that inhibition of IL-
17RA signaling could be used to potentiate the response to
chemotherapy, especially that involving agents such as 5-FU,
which induce IL-17A expression.
DISCUSSION
The IL-23-IL-17 axis plays a key role in tumor-associated inflam-
mation and cancer development (Alshaker and Matalka, 2011;
Martin-Orozco and Dong, 2009; Zou and Restifo, 2010). The
numbers of Th17 cells and expression of IL-17A are increased
in human glioma (Hu et al., 2011) and esophageal cancer
(Chen et al., 2012). Increased expression of IL-23, IL-17A, and
TGF-b1 indicates adverse prognosis and predicts a poor
response to chemotherapy in pancreatic carcinoma (Vizioc.
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Figure 6. Combined Treatment with Anti-IL-17A and 5-FU Results in a Stronger Therapeutic Effect
(A) CPC-APCmicewere treatedwith 5-FU (50mg/kg) for two consecutive days eachweek for 6 weeks. PBSwas used as a control. Colonic tumorswere analyzed
by qRT-PCR for IL-17A and IL-17F mRNAs.
(B and C) 3.5-month-old CPC-APCmice were treated with isotype control (Con), anti-IL-17A (Ab), 5-FU + isotype control (5-FU), or 5-FU + anti-IL-17A (Ab + 5-FU)
for 6 weeks and sacrificed for analysis of tumor parameters (B) (n = 8) and qRT-PCR analysis of IL-6 mRNA (C) (n = 21). (D and E) Five-month-old CPC-APC mice
were treated with isotype control (Con), anti-IL-17A (Ab), 5-FU + isotype control (5-FU), or 5-FU + anti-IL-17A (Ab + 5-FU) for 2 weeks and sacrificed. Colonic
tumors were embedded in paraffin blocks and analyzed for Ki-67 (D) and cleaved caspase 3 (E). Eight HMF images were used for quantification in (D) and (E). Data
are averages ± SEM. *p < 0.05. The scale bar represents 100 mm.
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IL-17RA Promotes Early Colorectal Tumorigenesiset al., 2012). Th17 cell abundance and IL-17 expression are also
elevated in gastric cancer and indicate a poor prognosis (Ya-
mada et al., 2012). In gastric cancer, CD8+ T cells also produce
IL-17A (Tc17 cells) and predict reduced overall and disease-free
survival (Zhuang et al., 2012). TAMs in gastric cancer promote
Tc17 development by producing IL-6, IL-23, and IL-1b, and IL-
17A induces cancer cells to produce CXCL12, which can attract
so-called myeloid-derived suppressor cells (MDSCs) or imma-
ture myeloid cells that seem to impede CD8+-dependent tumor
cytotoxicity (Zhuang et al., 2012). In human patients with stage
I or II colorectal cancer, a high ‘‘Th17 signature’’ confers drasti-
cally reduced disease-free survival after resection of primary tu-
mors (Tosolini et al., 2011). Despite ample evidence for the likely
involvement of IL-17 family members in cancer, the exact cell
type within which IL-17RA engagement promotes tumor devel-
opment and progression has not been identified for any cancer.
It is also not clear, especially in sporadic CRC and other cancers
that are not induced by underlying inflammation or infection, at
what stage of the tumorigenic process IL-17RA engagement
stimulates cancer development and progression.
Mechanistic proof that elevated IL-17 expression promotes
cancer development has come from studies of mouse models.
In a mouse model of CAC induced by pathogen (ETBF) infection
of ApcMin mice, antibody-mediated IL-17A neutralization
blocked ETBF-induced colitis and tumorigenesis (Wu et al.,
2009). IL-17A is also important for tumorigenesis in the AOM-
DSS model of CAC (Hyun et al., 2012; Tanaka et al., 2003;
Tong et al., 2012). However, in both of these models malignant
progression is driven by deliberately induced inflammation. In
ApcMin mice, in which sporadic colonic tumorigenesis does not
depend on deliberate induction of inflammation, both IL-17A
and F promote tumor development (Chae and Bothwell, 2011;
Chae et al., 2010). Ablation of Il17ra also reduced tumorigenesis
in the CPC-APC model of sporadic colorectal tumorigenesis, in
which CRC development depends on LOH at the Apc locus (Gri-
vennikov et al., 2012). IL-17RA, which dimerizes with IL-17RC
and IL-17RE, can be activated by IL-17A, C, and F and by IL-
25 (Iwakura et al., 2011). Il17a/ and Il17ra/ mice are also
resistant to chemically induced skin cancer (He et al., 2012;
Wang et al., 2010), and IL-17A promotes development of lung
cancer in mice (Chang et al., 2014). Microbiota-driven upregula-
tion of IL-17C also contributes to colonic tumor development
through autocrine induction of Bcl-2 and Bcl-xL in malignant en-
terocytes (Song et al., 2014). In our model, however, IL-17A is
mainly produced by tumor-infiltrating Th17 cells and ILCs,
whose expansion depends on IL-23 that is produced by TAMs
that were activated by microbial products (Grivennikov et al.,
2012). IL-23R is not expressed on adenoma epithelial cells,
and its pro-tumorigenic activity is exerted via IL-17RA-activating
cytokines. By contrast, IL-17RA is expressed on amuch broader
range of cells, which in addition to hematopoietic cells include
epithelial cells and fibroblasts. IL-17RA signaling in any of these
cell types can potentially promote tumor development. The re-
sults described above identify transformed epithelial cells that
had just lost APC expression as the main cellular site for the
pro-tumorigenic activity of IL-17RA. These conclusions are sup-
ported both by adoptive transfer experiments and by the specific
ablation of IL-17RA in IECs that have lost at least one Apc allele.
Although IL-17RA signaling also controls the expression of IL-61060 Immunity 41, 1052–1063, December 18, 2014 ª2014 Elsevier Inwithin colorectal tumors, whole-body Il6 ablation had only a mi-
nor effect on IL-17A expression and reduced tumor development
to a much lower extent than IL-17RA ablation. This stands in
marked contrast to the AOM+DSSCACmodel, where inflamma-
tion (DSS)-induced IL-6 signaling plays amajor role in tumorigen-
esis along with IL-11 (Bollrath et al., 2009; Grivennikov et al.,
2009; Putoczki et al., 2013). Importantly, in the CPC-APCmodel,
IL-6 does not play a critical role in induction of IL-17A expression,
and its function is likely to be replaced by that of IL-21 or IL-23
(Korn et al., 2009). Furthermore, IL-11 expression is not regu-
lated by IL-17RA signaling, and therefore IL-11 does not mediate
the pro-tumorigenic effect of IL-17 signaling downstream of
IL-17RA.
Identification of the site of action of IL-17RA had also revealed
how IL-17A drives tumor development. In the premalignant en-
terocyte that had lost expression of the Apc tumor suppressor
gene, IL-17RA signaling is required for induction of cell prolifer-
ation that drives the progression of premalignant ACF lesions
into adenomas. In the same cells, IL-17RA engagement acti-
vates ERK, p38, and NF-kB, signaling molecules that contribute
to cell proliferation and survival. IL-17RA engagement, however,
does not lead to direct STAT3 activation. Antibody-mediated
neutralization of IL-17A in 2-month-old CPC-APC mice, which
already harbor several ACF lesions and small adenomas (Hinoi
et al., 2007), resulted in amarked inhibition of tumor progression.
These results indicate that although IL-17A neutralization might
enhance colitis-associated mucosal injury (Yang et al., 2008)
and therefore might not be suitable for the treatment of IBD or
CAC, which occur in the context of ulcerative colitis, IL-17A
neutralization is suitable for the treatment and prevention of spo-
radic CRC, in which the inflammatory response is limited to the
tumor microenvironment and does not affect the surrounding
normal tissue. These results also demonstrate that IL-17RA
signaling, acting in cells that have just lost Apc expression,
already stimulates malignant progression at the very early ACF
stage.
Elevated expression of IL-17 cytokines has been linked to
resistance to both classical cytotoxic drugs and targeted thera-
peutics, such as the VEGF neutralizing antibody Avastin (Chung
et al., 2013). Our results indicate that treatment of mice with 5-
FU, a cytotoxic drug used in CRC treatment, results in elevated
IL-17A expression within colonic tumors and thus appears to
attenuate the therapeutic response. Notably, even a relatively
short treatment with an IL-17A-neutralizing antibody, which on
its own was insufficient to affect tumor development, syner-
gized with 5-FU treatment to elicit a reduction in tumor load.
These results suggest that IL-17A-neutralizing or IL-17RA-
blocking antibodies (secukinumab, ixekizumab, and brodalu-
mab), already proven effective in autoimmune disorders such
as psoriasis, psoriatic arthritis, and ankylosing spondylitis (Patel
et al., 2013), may be used as neo-adjuvants in the treatment of
early, nonmetastatic CRC. Although 5 year survival rates in
stage I and II CRC approach 90%, it seems likely that the
10% of stage I and II patients that progress to incurable meta-
static disease are those whose tumors display high IL-17
expression (Tosolini et al., 2011). These patients, with extremely
poor prognosis and reduced overall survival, are the ones who
are likely to benefit the most from anti-IL-17A-IL-17RA neoadju-
vant therapy.c.
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Generation of Il17raF/F Mice
Embryonic stem cells (ESCs; clones EPD0570_2_H07 and H08) of a C57BL/6
background and harboring an Il17raLacZ-Flox targeted allele were obtained from
the Knockout Mouse Project (KOMP) Repository at the University of California,
Davis. ESCs were injected into C57BL/6 albino blastocysts and transferred to
pseudopregnant females. Chimeric offspring were crossed to C57BL/6 albino
mice, and mice of the F1 generation were selected for transmission of the tar-
geted allele according to coat color and genotype. Il17raLacZ-Flox- positivemice
were crossed to a FLP deleter mouse (Rodrı´guez et al., 2000) so that the LacZ
and neo cassettes would be removed, resulting in an Il17raF strain where two
loxP sites flank exons 3 and 4 of Il17ra. Cre-mediated recombination of these
sites resulted in a frame shift and early termination of protein translation in exon
5 (Figure S4B). Genotyping of Il17ra WT and flox alleles was performed with
primers 1 (P1, 50-GGGGTTTTTGTTGTTGTTGG-30) and 2 (P2, 50-GCAGCTGTT
CTCAACCTTCC-30). Ablated Il17ra allele was detected by P1 and P3 (50-
GGCCAGGATCTACCACAAAG-30).
Mouse Models
C57BL/6 control mice were obtained from Charles River Laboratories.
Il17ra/ mice were from Amgen (Ye et al., 2001). VillinCre-ERT2 mice were ob-
tained from Dr. Sylvie Robine (el Marjou et al., 2004). ApcF/F, Cdx2Cre (CPC),
and Cdx2Cre-ERT2 mice have been described (Feng et al., 2011; Feng et al.,
2013; Hinoi et al., 2007). Il6/ (Kopf et al., 1994) and CD45.1 (Shen et al.,
1985) mice were obtained from Jackson Laboratory. For conditional ablation
of IL-17RA in colonic epithelial and tumor cells of CPC-APC mice, Il17raF/F
ApcF/F mice were crossed toCdx2Cre Il17ra+/mice, where the null Il17ra allele
is derived from the whole-body knockout strain (Ye et al., 2001). All mice were
maintained in filter-topped cages on autoclaved food and water at the Univer-
sity of California, San Diego (UCSD), and all experiments were performed in
accordance with UCSD and NIH guidelines and regulations. All experiments
used co-housed littermates so that consistency of common microflora would
be ensured.
Analysis of spontaneous CRC tumorigenesis was described (Grivennikov
et al., 2012). For tamoxifen-inducible tumorigenesis, CDX2Cre-ERT2 ApcF/F
mice were given 70 mg/kg body weight tamoxifen (Sigma; dissolved in 5%
ethanol, 95% corn oil) intraperitoneally on a daily basis for three consecutive
days. Mice were sacrificed 1–4 weeks after the last dose of tamoxifen for his-
tological analysis and tumor statistics.
Bone-Marrow Transplantation
Six- to eight-week-old recipient mice were irradiated twice during one day to
achieve a lethal dose (23 600 rad) and intravenously injected with a single-cell
suspension of 107 donor bone-marrow cells. Recipients were co-housed litter-
mates, which were transplanted with both gene-deficient and wild-type bone-
marrow for comparison. After transplantation, the recipients were placed on
sulphamethoxazole and trimethoprime in drinking water for two weeks, fol-
lowed by transfer to cages that were from the same room and rack but that
had dirty bedding so that microflora would be restored. Mice were sacrificed
and analyzed for tumor development 3–4 months after transplantation.
Antibody and 5-FU Treatment in Mice
For the spontaneous CRCmodel, IL-17A-neutralizing antibody or isotype con-
trol antibody (Bio X Cell) were intraperitoneally injected at a dose of 500 mg on a
weekly basis until sacrifice. For the tamoxifen-inducible model of tumorigen-
esis, antibodies (500 mg) were injected one day after the last tamoxifen dose
and then on a weekly basis until sacrifice. 5-FU was given intraperiotenally
at 50 mg/kg body weight each day for two consecutive days, and the scheme
was repeated every week. For combined treatment of the spontaneous CRC
model with antibody and 5-FU, antibody and 5-FU were injected on the first
day of the week, and the second dose of 5-FU was given on the second day
of the week. Treatment was repeated weekly. In all cases isotype antibody
was used as a control, and PBS was used as vehicle control for 5-FU.
Antibodies and Stains
Fluorescent-labeled antibodies for flow cytometry were from eBioscience.
Immunoblot analysis and immunohistochemistry were performed withImmantibodies to Ki-67, MUC2 (GeneTex), active caspase 3, ERK1/2, phospho-
ERK1/2, phospho-p38, phospho-JNK, phospho-NF-kB p65, phospho-
STAT3, phosphor-Akt S473, phosphor-Akt T308 (Cell Signaling), b-catenin,
HDAC1, NF-kB p65, p38 (Santa Cruz Biotechnology), CD11b, gp38, Lyve1,
EpCam (eBioscience), CD31 (BD), a-smooth muscle actin (Abcam), and
a-tubulin (Sigma). For fluorescent microscopy, secondary antibodies (host:
donkey) labeled with Alexa 488 or 594 were from Life Technology. For ELISA
analysis of IL-6, colonic tumors were cultured in DMEM containing 10% fetal
bovine serum (FBS) overnight, and supernatant was analyzed with a IL-6
ELISA kit from eBioscience. Cytokine concentration was normalized to the
weight of tumors in each well.
Cell Culture and Cytokine Treatment
Organoid culture of small-intestinal crypts has been previously described
(Sato et al., 2009). In brief, crypts were isolated from small intestines of
VillinCre-ERT2 ApcF/F mice. Organoids were plated in Matrigel (BD Bioscience)
and maintained in DMEM/F12 media (Life Technologies) containing B27 and
N2 supplements (Life Technologies), 1.25 mM N-acetyl L-cysteine (Sigma),
100 ng/ml noggin (Peprotech), 50 ng/ml mEGF (Biosource), and 10%
Rspo1-Fc-conditioned medium. The Rspo1-Fc-expressing cell line was a
generous gift from Dr. Calvin Kuo (Stanford). APC inactivation in organoids
was induced with 1 mM 4-hydroxytamoxifen (Sigma). Two days after APC
inactivation, organoids were maintained in DF+++ (DMEM/F12 media sup-
plemented with GlutaMAX, HEPES, and penicillin-streptomycin). For the
study of IL-17 signaling in vitro, APC-inactivated organoids were replen-
ished with fresh DF+++ 3 hr before being treated with 50 ng/ml recombinant
human IL-17A for indicated periods and lysed for immunoblotting analysis.
CAFs were purified from CPC-APC tumors by magnetic-bead-mediated
depletion of EpCam+ and CD45+ cells and cultured in DMEM containing
10% FBS.
Flow Cytometry and Cell Sorting
Isolated immune cells were stained with labeled antibodies in PBS with 2%
FCS and analyzed on BD LSRII or on a Beckman Coulter Cyan ADP flow cy-
tometer. Dead cells were excluded on the basis of staining with Live/Dead
fixable dye (eBioscience). IECs were purified by EpCam labeling followed by
biotin-positive selection with magnetic beads (Stemcell). Purified IECs were
subjected to flow-cytometic analysis, and more than 90% of them were
EpCam+.
Quantitative RT-PCR Analysis
Total RNA was extracted with the RNeasy Plus kit (QIAGEN) and reverse tran-
scribed with an IScript kit (Biorad). quantitative RT-PCR (qRT-PCR) was per-
formed with Soofast EvaGreen supermix (Biorad) on a Biorad CFX96machine.
Expression data were normalized to RPL32 mRNA levels. The data are pre-
sented in arbitrary units andwere calculated as 2(Ct(RPL32 – gene of interest)). Primer
sequences are listed in Table S1 and generally were obtained from the NIH
qPrimerDepot (http://mouseprimerdepot.nci.nih.gov). Whenever possible,
primers were intron spanning, such that amplification was only feasible on
complementary DNA.
Statistical Analysis
Data are presented as averages ± SEM and were analyzed with a Student’s
t test. p values less than 0.05 were considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and one table and can
be found with this article online at http://dx.doi.org/10.1016/j.immuni.2014.
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